• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    7/25/23 5:32:21 PM ET
    $ADIL
    $CLGN
    $ETAO
    $FRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties
    Health Care
    Get the next $ADIL alert in real time by email

    Gainers

    • 9 Meters Biopharma (NASDAQ:NMTR) stock rose 36.8% to $0.1 during Tuesday's after-market session. At the close, 9 Meters Biopharma's trading volume reached 4.7 million shares. This is 1095.7% of its average volume over the last 100 days. The company's market cap stands at $1.4 million.
    • ViewRay (NASDAQ:VRAY) stock moved upwards by 11.99% to $0.03. Trading volume for this security closed at 19.2 million, accounting for 150.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $5.1 million.
    • Plus Therapeutics (NASDAQ:PSTV) stock increased by 10.36% to $2.45. The company's market cap stands at $6.1 million.
    • PAVmed (NASDAQ:PAVM) shares moved upwards by 7.57% to $0.4. The company's market cap stands at $42.0 million.
    • CollPlant Biotechnologies (NASDAQ:CLGN) shares increased by 7.3% to $6.46. The company's market cap stands at $73.5 million.
    • NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 6.95% to $0.4. The company's market cap stands at $27.8 million.

    Losers

    • INVO Bioscience (NASDAQ:INVO) stock decreased by 16.5% to $0.13 during Tuesday's after-market session. Trading volume for this security closed at 112.1K, accounting for 8.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.1 million.
    • Adial Pharmaceuticals (NASDAQ:ADIL) stock fell 6.33% to $0.25. At the close, Adial Pharmaceuticals's trading volume reached 50.8K shares. This is 2.2% of its average volume over the last 100 days. The company's market cap stands at $7.4 million.
    • Etao International Co (NASDAQ:ETAO) shares decreased by 5.36% to $0.53. Etao International Co's trading volume hit 109.0K shares by close, accounting for 17.8% of its average volume over the last 100 days. The company's market cap stands at $54.2 million.
    • Fresh Tracks Therapeutics (NASDAQ:FRTX) stock fell 4.83% to $0.77. The company's market cap stands at $4.5 million.
    • Myomo (AMEX:MYO) shares decreased by 4.6% to $0.76. The company's market cap stands at $15.9 million.
    • ThermoGenesis Holdings (NASDAQ:THMO) stock fell 4.48% to $1.28. The company's market cap stands at $2.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADIL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADIL
    $CLGN
    $ETAO
    $FRTX

    CompanyDatePrice TargetRatingAnalyst
    PLUS THERAPEUTICS Inc.
    $PSTV
    2/3/2026$2.00Buy
    Lake Street
    NRX Pharmaceuticals Inc.
    $NRXP
    9/8/2025$40.00Buy
    H.C. Wainwright
    PLUS THERAPEUTICS Inc.
    $PSTV
    9/3/2025$5.00Hold → Buy
    D. Boral Capital
    NRX Pharmaceuticals Inc.
    $NRXP
    4/2/2025$18.00Buy
    BTIG Research
    PLUS THERAPEUTICS Inc.
    $PSTV
    3/17/2025$9.00Buy
    D. Boral Capital
    Adial Pharmaceuticals Inc
    $ADIL
    11/14/2024$8.00Buy
    Rodman & Renshaw
    Myomo Inc.
    $MYO
    7/31/2024$7.00Buy
    Craig Hallum
    Myomo Inc.
    $MYO
    5/20/2024$7.00Buy
    Lake Street
    More analyst ratings

    $ADIL
    $CLGN
    $ETAO
    $FRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Plus Therapeutics with a new price target

    Lake Street initiated coverage of Plus Therapeutics with a rating of Buy and set a new price target of $2.00

    2/3/26 8:52:26 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    H.C. Wainwright initiated coverage on NRx Pharmaceuticals with a new price target

    H.C. Wainwright initiated coverage of NRx Pharmaceuticals with a rating of Buy and set a new price target of $40.00

    9/8/25 8:58:39 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Plus Therapeutics upgraded by D. Boral Capital with a new price target

    D. Boral Capital upgraded Plus Therapeutics from Hold to Buy and set a new price target of $5.00

    9/3/25 8:18:22 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $ADIL
    $CLGN
    $ETAO
    $FRTX
    SEC Filings

    View All

    PLUS THERAPEUTICS Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

    4/2/26 4:30:12 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    SEC Form DEFA14A filed by PLUS THERAPEUTICS Inc.

    DEFA14A - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

    3/31/26 4:30:19 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    SEC Form DEF 14A filed by PLUS THERAPEUTICS Inc.

    DEF 14A - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

    3/31/26 4:20:15 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $ADIL
    $CLGN
    $ETAO
    $FRTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio

    Medtech industry veteran to oversee development and commercialization of PAVmed's current and future medical device portfolio.Octeris, Inc. subsidiary formed to advance endoscopic esophageal imaging technology recently licensed from Duke University.NEW YORK, April 2, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has appointed medical technology industry veteran Joseph Virgilio as Senior Vice President and Chief Business Officer, Medical Devices to oversee the development and commercialization of PAVmed's cur

    4/2/26 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives

    HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), today announces a new payer coverage agreement with Highmark, effective April 1, 2026, providing reimbursement for its CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay for patients with metastatic central nervous system cancers. Highmark joins a growing list of national and regional payers, including United Healthcare and Humana, that provide coverage for CNSide. The addition of Highmark expands CNSide's total covered lives from approximately 67 million to 75 million, representing continued progress toward t

    4/2/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced that it has granted inducement awards to two new employees who recently joined the Company. The awards were granted on March 26, 2026 under the Company's 2015 New Employee Incentive Plan, as amended, which provides for the granting of equity awards to new employees as an inducement to join the Company. The inducement awards consist in the aggregate of options to purchase 300,000 shares of Company common stock and 300,000 restricted stoc

    3/31/26 4:30:00 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $ADIL
    $CLGN
    $ETAO
    $FRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Aklog Lishan

    4 - PAVmed Inc. (0001624326) (Issuer)

    4/3/26 6:53:45 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Mcgrath Dennis M

    4 - PAVmed Inc. (0001624326) (Issuer)

    4/3/26 4:51:51 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Glennon Michael J

    4 - PAVmed Inc. (0001624326) (Issuer)

    4/3/26 4:50:30 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    $ADIL
    $CLGN
    $ETAO
    $FRTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Getz Heather C bought $13,972 worth of shares (20,000 units at $0.70), increasing direct ownership by 18% to 131,754 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    3/17/26 5:39:28 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Director Kirk Thomas F bought $51,113 worth of shares (72,000 units at $0.71), increasing direct ownership by 15% to 553,857 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    3/16/26 6:08:14 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Director Getz Heather C bought $50,960 worth of shares (70,000 units at $0.73), increasing direct ownership by 168% to 111,754 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    3/12/26 5:18:01 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $ADIL
    $CLGN
    $ETAO
    $FRTX
    Leadership Updates

    Live Leadership Updates

    View All

    PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio

    Medtech industry veteran to oversee development and commercialization of PAVmed's current and future medical device portfolio.Octeris, Inc. subsidiary formed to advance endoscopic esophageal imaging technology recently licensed from Duke University.NEW YORK, April 2, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has appointed medical technology industry veteran Joseph Virgilio as Senior Vice President and Chief Business Officer, Medical Devices to oversee the development and commercialization of PAVmed's cur

    4/2/26 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced that it has granted inducement awards to two new employees who recently joined the Company. The awards were granted on March 26, 2026 under the Company's 2015 New Employee Incentive Plan, as amended, which provides for the granting of equity awards to new employees as an inducement to join the Company. The inducement awards consist in the aggregate of options to purchase 300,000 shares of Company common stock and 300,000 restricted stoc

    3/31/26 4:30:00 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered "Depression Thermometer" Across its Interventional Psychiatry Network

    Hope Therapeutics ((subsidiary of NRx Pharmaceuticals, NASDAQ:NRXP) partners with Emobot Health to deploy its AI-powered "Depression Thermometer" across its interventional psychiatry clinic network.Emobot's platform passively monitors depression, bipolar disorder and anxiety disorders via smartphone — replacing burdensome questionnaires with background analysis of facial expressions, vocal tones, and actigraphy.The partnership targets the critical "blind spot" in TRD care: ~50% of patients relapse within 6–12 months, often undetected between clinic visits.Clinical validation across three prospective studies shows strong concordance with MADRS (r=0.89) and PHQ-9 (r=0.83), providing an objecti

    3/30/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $CLGN
    $ETAO
    $FRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Adial Pharmaceuticals Inc

    SC 13G/A - ADIAL PHARMACEUTICALS, INC. (0001513525) (Subject)

    11/14/24 3:44:01 PM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by PAVmed Inc.

    SC 13G - PAVmed Inc. (0001624326) (Subject)

    11/14/24 10:02:46 AM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Myomo Inc.

    SC 13G/A - MYOMO, INC. (0001369290) (Subject)

    10/18/24 2:21:35 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $ADIL
    $CLGN
    $ETAO
    $FRTX
    Financials

    Live finance-specific insights

    View All

    PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    PAVmed strengthened its capital structure and relaunched its medical device portfolio under new leadership Veris Health advanced strategic partnership with OSU and progressed implantable physiological monitor toward FDA submissionLucid Diagnostics expanded EsoGuard healthcare system access and clinical evidence base Conference call and webcast to be held today, March 30, at 8:30 AM ESTNEW YORK, March 30, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagno

    3/30/26 8:00:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    Processed 3,664 EsoGuard® tests and recognized 4Q25 revenue of $1.5 millionExpanded EsoGuard access with U.S. Department of Veterans Affairs contract award and strengthened clinical evidence with positive data from the largest reported real-world experience of esophageal precancer detectionConference call and webcast to be held today, March 26, at 8:30 AM ESTNEW YORK, March 26, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM) ("PAVmed"), today provided a business update for the Company and reported financial results for the fourth quarter and full

    3/26/26 8:00:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress

    Key highlights for the first full year of operation under the new management team include: A year-over-year reduction in operating expenses with $7.8 Million cash on hand at year end. With ongoing revenue from operations and current ATM trends, the Company anticipates adequate resources to support operations through 2026, with anticipation of continued revenue growth. As of December 31, 2025, all previously issued convertible debt had been converted into common stock.Anticipated FDA approval of at least one new drug – Preservative Free Ketamine under an ANDA—during Q3 2026. A favorable preliminary bioequivalence determination was received from the FDA last week.A Type C in-person meeting wi

    3/24/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care